Dogwood Therapeutics, Inc. 8-K

What Happened
Dogwood Therapeutics, Inc. held a Special Meeting on March 11, 2026 and announced (filed on March 12, 2026) that shareholders approved the potential exercise of an unregistered common stock warrant to purchase up to 4,386,037 shares and the issuance of common stock upon exercise. The vote also approved the adjournment of the Special Meeting if needed. The approvals were given to comply with the terms of a Securities Purchase Agreement dated January 11, 2026 and for purposes of Nasdaq Listing Rule 5635(d).

Key Details

• Record date: February 12, 2026; quorum: 29,310,309 shares present in person or by proxy, representing 88.03% of voting power.
• Warrant approval vote: For 29,286,786; Against 19,057; Abstain 4,466; Broker non-votes: none.
• Adjournment approval vote: For 29,283,790; Against 21,571; Abstain 4,948; Broker non-votes: none.
• The warrant and related approval arise from a Securities Purchase Agreement dated January 11, 2026 with a single institutional investor.

Why It Matters
Shareholder approval clears a Nasdaq-related condition and allows Dogwood to issue up to 4,386,037 shares if the unregistered warrant is exercised, which would increase the company’s outstanding shares and could be dilutive to existing holders. This filing does not indicate that the warrant has been exercised or that shares have been issued—rather, it authorizes future issuance under the terms approved. Investors should watch for subsequent filings reporting any exercise, issuance, or related changes to share count or capital structure.